Oncotype DX Recurrence Score as an Informative Tool to Optimize Neoadjuvant Therapy in HR-positive, HER2negative Breast Cancers

被引：0
|
作者：
Luzhna, Lidiya
Chia, Stephen
Pauls, Mehrnoosh
Levasseur, Nathalie
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-15-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-15-04
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study
    Guerrero-Zotano, A.
    Perez-Garcia, J. M.
    Ruiz-Borrego, M.
    Bermejo, B.
    Gil-Gil, M.
    de la Haba, J.
    Conejo, E. Alba
    Quiroga, V
    Caranana, V
    Urruticoechea, A.
    Morales, S.
    Bellet, M.
    Anton, A.
    Fernandez-Abad, M.
    Sanchez-Rovira, P.
    Calabuig, L.
    Perez-Escuredo, J.
    Sampayo-Cordero, M.
    Cortes, J.
    Llombart-Cussac, A.
    ESMO OPEN, 2024, 9 (10)
  • [2] Informative tools to optimize neoadjuvant therapy in ER positive, HER2 negative breast cancers.
    Luzhna, Lidiya
    Chia, Stephen
    Pauls, Mehrnoosh
    LeVasseur, Nathalie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database
    Cheng, Ran
    Kong, Xiangyi
    Wang, Xiangyu
    Fang, Yi
    Wang, Jing
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [4] Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
    Garufi, Giovanna
    Carbognin, Luisa
    Arcana, Concetta
    Parola, Sara
    Ventriglia, Anna
    Doronzo, Antonio
    Garutti, Mattia
    Orlandi, Armando
    Palazzo, Antonella
    Fabi, Alessandra
    Bria, Emilio
    Tortora, Giampaolo
    Arpino, Grazia
    Giuliano, Mario
    Del Mastro, Lucia
    De Laurentiis, Michelino
    Puglisi, Fabio
    CANCER TREATMENT REVIEWS, 2022, 110
  • [5] Systemic Therapy of HR-positive, HER2-negative metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03) : 257 - 257
  • [6] Ribociclib in HR-positive, HER2-negative breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2016, 17 (11): : E482 - E482
  • [7] Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25)
    Abu-Khalaf, Maysa M.
    Aderhold, Kimberly
    Marczyk, Michal
    Chung, Gina
    Hofstatter, Erin
    Sanft, Tara
    Silber, Andrea
    DiGiovanna, Michael
    Zelterman, Daniel
    Puzstai, Lajos
    Hatzis, Christos
    CANCER RESEARCH, 2020, 80 (04)
  • [8] In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry
    Tyburski, Haley
    Karakas, Cansu
    Finkelman, Brian S.
    Turner, Bradley M.
    Zhang, Huina
    Hicks, David G.
    LABORATORY INVESTIGATION, 2024, 104 (03)
  • [9] The Relation between Melatonin MT1 Receptor and Oncotype Recurrence Score in HER 2-Positive and Negative Breast Cancers
    Oprea-Ilies, G. M.
    Haus, E.
    McLendon, L. A.
    Sackett-Lundeen, L. L.
    Busch, R.
    Adams, A.
    Cohen, C.
    LABORATORY INVESTIGATION, 2012, 92 : 56A - 56A
  • [10] The Relation between Melatonin MT1 Receptor and Oncotype Recurrence Score in HER 2-Positive and Negative Breast Cancers
    Oprea-Ilies, G. M.
    Haus, E.
    McLendon, L. A.
    Sackett-Lundeen, L. L.
    Busch, R.
    Adams, A.
    Cohen, C.
    MODERN PATHOLOGY, 2012, 25 : 56A - 56A
12345